Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IMNM

Immunome, Inc.

Healthcare | Biotechnology

No licensed closing price on file for IMNM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.54

Immunome, Inc. (NASDAQ: IMNM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 19:24 UTC.

What Immunome, Inc. does

Immunome is a biotechnology company developing targeted cancer therapies, with particular expertise in antibody-drug conjugates and other oncology treatments. The company's lead asset, varegacestat, is an oral therapy for desmoid tumors that recently met its primary endpoints in a Phase 3 trial, with an anticipated regulatory submission planned. The pipeline also includes clinical and preclinical programs targeting various cancer types, supported by internal capabilities in discovery, design, development, and manufacturing of therapeutics.

Summarized from Immunome, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.54

Revenue, margins & earnings

FY2023: net loss $107M on revenue $14M$14MFY2023FY2024: net loss $293M on revenue $9M$9MFY2024FY2025: net loss $212M on revenue $7M$7MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-15
  • 2026-09-15Chief Scientific OfficerEmployee Stock Option (right to buy)Option exercise18,000—
  • 2026-09-15Chief Scientific OfficerSale-13,200$334.2K
  • 2026-09-15Chief Scientific OfficerGift-8,800—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Immunome, Inc. do?

Immunome is a biotechnology company developing targeted cancer therapies, with particular expertise in antibody-drug conjugates and other oncology treatments.

When did IMNM last file with the SEC?

Immunome, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 19:24 UTC. This page is also available as JSON at /api/data?ticker=IMNM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IMNM and 5,000+ tickers.

Create a free account — keep IMNM
For your agent
GET /api/data?ticker=IMNM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt